Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.35 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402325 | 0.89 | HPGD (0.50) | HPGDUSP2ALDH1A1KDM4EMAPT | |
| SCHEMBL25230096 | 0.88 | USP2 (0.43) | HPGDUSP2ALDH1A1KDM4EMAPT | |
| SCHEMBL3646039 | 0.88 | USP2 (0.43) | HPGDUSP2ALDH1A1KDM4EMAPT | |
| SCHEMBL16748916 | 0.88 | HPGD (0.49) | HPGDUSP2ALDH1A1KDM4EMAPT | |
| SCHEMBL22235969 | 0.87 | HPGD (0.40) | HPGDUSP2ALDH1A1KDM4EBTK | |
| SCHEMBL14647352 | 0.86 | HPGD (0.48) | HPGDUSP2ALDH1A1KDM4EMAPT | |
| SCHEMBL17893267 | 0.86 | HPGD (0.41) | HPGDUSP2ALDH1A1KDM4ECDK9 | |
| SCHEMBL17893265 | 0.86 | HPGD (0.41) | HPGDUSP2ALDH1A1KDM4ECDK9 | |
| SCHEMBL16748878 | 0.84 | MAPT (0.46) | HPGDUSP2ALDH1A1KDM4EMAPT | |
| SCHEMBL17896136 | 0.82 | KDM4E (0.41) | HPGDUSP2ALDH1A1KDM4EBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240572-B1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170362243-A1 | BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3240572-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240545-A1 | BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109223-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109219-A1 | BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362243-A1 | BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS | BTK, ABL1, SYK | HPGD 3884/4885USP2 3052/4885ALDH1A1 4316/4885 |
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | BTK, SYK, ABL1 | HPGD 3385/4885USP2 2668/4885ALDH1A1 3567/4885 |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | BTK, SYK, ABL1 | HPGD 3385/4885USP2 2668/4885ALDH1A1 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.